ELISA – Products

Drug product glycosylation is a critical quality attribute (CQA) due to its potential impact on pharmacokinetics properties and stability of the product. The ability to view and choose from desired titer and glycosylation profiles at the same time provides more in-depth knowledge that facilitates more informed decisions.

Selectins are actively involved in constitutive lymphocyte homing, chronic and acute inflammation, and cancer metastasis. Therefore, they are current hot targets for developing therapeutics to treat various diseases, such as sickle cell disease and malignancies.

Download this app note to explore various solutions designed to improve COVID-19 detection and the development of vaccines and therapeutics.

At high levels, host cell proteins (HCPs) can cause immunogenic responses and reduced efficacy of biologics, so it is imperative to have an effective, robust HCP assay to detect them and mitigate these effects.

Sino Biological, Inc. has announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047. A total of 17 million shares were issued for a total of 4.98 billion RMB raised during this initial public offering.

Download this whitepaper to discover how next-generation ELISA technology can accelerate biomarker discovery and provide in-depth analysis of COVID-19 host cytokine levels.

Download this app note to discover an automated SARS-CoV-2 IgG Ab ELISA workflow that delivers stable assay performance across the entire plate and produces more than 1,000 results in 11 hours.

Avacta Group plc is pleased to announce that Avacta Life Sciences’ diagnostics division has achieved ISO 13485 certification for the quality management system for the manufacture and distribution of Affimer reagents for use in lateral flow, ELISA and immunodiagnostic in-vitro diagnostic devices.